Navigation Links
Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Date:1/31/2008

tual results to differ materially from those in the forward-

looking statements. Such risks and uncertainties include, among others,

the availability of funds and resources to pursue research and

development projects, the efficacy of REOLYSIN(R) as a cancer treatment,

the tolerability of REOLYSIN(R) outside a controlled test, the success

and timely completion of clinical studies and trials, the Company's

ability to successfully commercialize REOLYSIN(R), uncertainties related

to the research and development of pharmaceuticals and uncertainties

related to the regulatory process. Investors should consult the Company's

quarterly and annual filings with the Canadian and U.S. securities

commissions for additional information on risks and uncertainties

relating to the forward-looking statements. Investors are cautioned

against placing undue reliance on forward-looking statements. The Company

does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
3. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
6. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
7. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
10. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
11. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
(Date:8/20/2014)... to biotechnology firms has revealed early bottlenecks on ... the researchers suggest that better communication of basic ... to faster commercialization down the road. , Biopharmaceutical ... university laboratories and licensed to biotechnology firms. Bottlenecks ... a high failure rate. But a new study ...
(Date:8/20/2014)... time, chemists have succeeded in measuring vibrational motion of ... study reveals how vibration of a single molecule differs ... The study was performed at the University of California, ... of Jyvskyl works as a visiting fellow under professor ... The second team was lead by Professor Eric O. ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2
... Ind., Jan. 23 Zimmer Holdings, Inc.,(NYSE: ZMH ... announced,today it will be participating in the Wachovia Securities ... 10:15 a.m. Eastern Time., A live webcast of ... at http://investor.zimmer.com . The webcast will,be archived for ...
... QED International Associates, Inc.,administrator for the HealthShares(TM) ... HealthShares(TM) Exchange-Traded Funds, today announced,that effective at the ... Pharmaceuticals Inc. (Nasdaq: REGN ) will replace ... HealthShares(TM) Composite Index. MGI Pharma is being,acquired by ...
... 23 /PRNewswire/ - Dalton Medicinal Chemistry Partners,the ... announces that it,has achieved another targeted milestone ... (Canada) Ltd., Dalton Medicinal Chemistry Partners ... and synthesize novel compounds against an,antiviral target ...
Cached Biology Technology:QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes 2
(Date:8/21/2014)... Ever heard of the water window? It consists of ... are not absorbed by the water in biological tissues. ... develop coherent radiations within the water window. These could ... a high-contrast image of the biological samples or to ... study identifies the physical mechanism needed to efficiently generate ...
(Date:8/21/2014)... designed by an international standards process, will be available ... an invited review published in the OnlineFirst version of ... the official journal of the American Society for Parenteral ... reduce the occurrence of misconnection that can be harmful ... are used to join medical devices, components, and accessories ...
(Date:8/21/2014)... a novel and versatile modeling strategy to simulate polyelectrolyte ... as well as for studying polyelectrolytes, including DNA and ... much larger and more complex polyelectrolyte systems, and to ... author of a paper on the work and a ... and Engineering. "This is a big step forward for ...
Breaking Biology News(10 mins):Water window imaging opportunity 2New feeding tube connectors will improve patient safety 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... European College of Neuropsychopharmacology (ECNP) is pleased to announce ... 2010 ECNP Lifetime Achievement Award in recognition of his ... diseases and neuropsychiatric drug development. The ECNP Lifetime Achievement ... impact on the field of neuropsychopharmacology. The award is ...
... firms and other life science organizations are ... environments and developing more sustainable operations, reports ... (GEN). This promising trend was made clear ... discussions that took place at GEN,s ( ...
... A new study from the Center for Interdisciplinary ... an additional link between Light At Night (LAN) and ... carried out at the University of Haifa that also ... to ,environmental light pollution, which the study has shown ...
Cached Biology News:Moussa B.H. Youdim wins the 2010 ECNP Lifetime Achievement Award 2GEN reports on the greening of the life sciences 2Connection between light at night (LAN) and cancer revealed in additional study 2
... FastPlax Antibody is used to detect the ... surface of infected cells as early as ... of the FastPlax Titer Kit, which allows ... hours. The FastPlax Antibody can ...
Alexa Fluor 647 anti-mouse IL-12 (Interleukin-12) / IL-23 (Interleukin-23) p40 25 ug...
PKC (pSer345), phospho-specific...
PE Rat anti-Hu CD267 Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: